Response to: intrapulmonary lymph node retrieval

Christina Brzezniak, Giuseppe Giaccone


The heterogenous non-small cell lung cancer (NSCLC) patient population harboring N1 metastatic disease provides both diagnostic and treatment challenges. The wide range of 5-year overall survival (OS) for this diverse group, from 27-67%, clearly illustrates the need for better prognostic, diagnostic and/or treatment modalities (1).